BlackRock Fund Advisors’s Theriva Biologics TOVX Stock Holding History

BlackRock Fund Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.87M	Buy	280 +45	+19%	+$462K	﹤0.01%	3177
2016 Q3	$3.53M	Buy	235 +10	+4%	+$150K	﹤0.01%	3016
2016 Q2	$3.54M	Buy	225 +209	+1,306%	+$3.93M	﹤0.01%	3002
2016 Q1	$339K	Sell	16 -2	-11%	-$30.1K	﹤0.01%	3306
2015 Q4	$352K	Buy	18 +1	+6%	+$21.2K	﹤0.01%	3343
2015 Q3	$329K	Buy	17 +1	+6%	+$24.6K	﹤0.01%	3305
2015 Q2	$388K	Sell	16 -2	-11%	-$40.1K	﹤0.01%	3276
2015 Q1	$340K	Sell	18 -1	-5%	-$17.9K	﹤0.01%	3348
2014 Q4	$242K	Buy	19 +5	+36%	+$67.2K	﹤0.01%	3430
2014 Q3	$222K	Buy	14 +2	+17%	+$32.5K	﹤0.01%	3433
2014 Q2	$185K	Hold	12	–	–	﹤0.01%	3514
2014 Q1	$268K	Buy	12 +4	+50%	+$82.8K	﹤0.01%	3385
2013 Q4	$101K	Buy	8 +1	+14%	+$12.6K	﹤0.01%	3573
2013 Q3	$106K	Hold	7	–	–	﹤0.01%	3542
2013 Q2	$100K	Buy	+7	New	+$95.7K	﹤0.01%	3525

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Fund Advisors's TOVX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Theriva Biologics (TOVX) stake by 19% in Q4 2016, buying an estimated $462K and bringing the position to 280 shares worth $1.87M. The position accounts for ﹤0.01% of the portfolio, ranked #3177.

BlackRock Fund Advisors first reported a position in TOVX in Q2 2013 and has held it in 15 quarters since. The position peaked at $3.54M in Q2 2016. 70 funds tracked by Wall St. Rank hold TOVX as of Q4 2016.

BlackRock Fund Advisors held 280 shares of Theriva Biologics worth $1.87M as of Q4 2016.
BlackRock Fund Advisors bought 45 Theriva Biologics shares in Q4 2016, an estimated $462K.
Theriva Biologics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3177 holding.
BlackRock Fund Advisors first reported a position in Theriva Biologics in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Theriva Biologics position peaked at $3.54M in Q2 2016.
70 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.